BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent



Status:Active, not recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:4/19/2017
Start Date:April 2014
End Date:April 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

BK Virus in Salivary Gland Disease

The purpose of this study is to analyze BK viral infection in salivary gland diseases;
specifically, to determine a definitive relationship between BK Virus and HIV associated
salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1
to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary
function/protein secretion will be correlated with BK polyomavirus titers. We expect that
patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit
from Ciprofloxacin.


Inclusion Criteria:

- HIV positive with Salivary Gland Disease

- Ability to read and understand English

Exclusion Criteria:

- Allergy to the family of fluoroquinolones (including ciprofloxacin)

- Currently taking tizanidine

- Concurrently taking antiacids containing magnesium hydroxide or aluminum hydroxide

- Current use of Theophylline

- Previous tendon disorder such as Rheumatoid arthritis

- History of seizures

- Current use of phenytoin

- Current use of glyburide

- Current use of methotrexate

- Severe renal impairment (known creatinine clearance < 30 or on dialysis)
We found this trial at
1
site
The University of North Carolina School of Dentistry
Chapel Hill, North Carolina 27599
Principal Investigator: Jennifer Webster-Cyriaque, DDS, PhD
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials